Biomarkers in acute heart failure-state of the art

Nature Reviews Cardiology

Volumn 9, Issue 8, 2012, Pages 478-490

  Maisel, Alan S ^a   Choudhary, Rajiv ^a  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; COPEPTIN; GALECTIN 3; KIDNEY INJURY MOLECULE 1; NATRIURETIC FACTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROADRENOMEDULLIN; PROCALCITONIN; PROTEIN S100B; ST2 PROTEIN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; TROPONIN; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; COMORBIDITY; DIAGNOSTIC ACCURACY; DISEASE MARKER; EMERGENCY WARD; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CALCITONIN; GLYCOPEPTIDES; HEART FAILURE; HUMANS; INFLAMMATION; MEMBRANE GLYCOPROTEINS; NATRIURETIC PEPTIDES; PROTEIN PRECURSORS; RECEPTORS, VIRUS; RISK ASSESSMENT;

EID: 84864287444     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.60     Document Type: Review

References (129)

1. Lloyd-Jones, D. et al. Heart disease and stroke statistics-2009 update. A report from the American Heart association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119, 480-486 (2009).
2. Metra, M. et al. Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy. Int. J. Cardiol. 144, 175-179 (2010).
3. Rudiger, A. et al. Acute heart failure: clinical presentation, one-year mortality and prognostic factors. Eur. J. Heart Fail. 7, 662-670 (2005). (Pubitemid 40733001)
4. Follath, F. et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med. 37, 619-626 (2011).
5. Gheorighade M. et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am. J. Cardiol. 96, 11G-17G (2005).
6. Latour-Perez, J., Coves-Orts, F. J., Abad-Terrado, C., Abraira, V. & Zamora, J. Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review. Eur. J. Heart Fail. 8, 390-399 (2006). (Pubitemid 43842121)
7. Adams, K. F. Jr et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 149, 209-216 (2005). (Pubitemid 40348525)
8. Fonarrow, G. C., Heywood, J. T., Heidenreich, P. A., Lopatin, M. & Yancy, C. W. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated National Registry (ADHERE). Am. Heart J. 153, 1021-1028 (2007). (Pubitemid 46809844)
9. De Luca, L. et al. Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy. Heart Fail. Rev. 12, 97-104 (2007). (Pubitemid 46916954)
10. Weintraub, N. L. et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation 122, 1975-1996 (2010).
11. Cotter, G., Felker, G. M., Adams, K. F., Milo-Cotter, O. & O'Connor, C. M. The pathophysiology of acute heart failure-is it all about fluid accumulation? Am. Heart J. 155, 9-18 (2008). (Pubitemid 350234787)
12. Collins, S. P., Lindsell, C. J., Storrow, A. B. & Abraham, W. T. for the HERE Scientific Advisory Committee, Investigators and Study Group. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann. Emerg. Med. 47, 13-18 (2006). (Pubitemid 43011322)
13. Parekh, N. & Maisel, A. S. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure. Curr. Opin. Cardiol. 24, 155-160 (2009).
14. Atkinson, A. J. et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001). (Pubitemid 32225406)
15. Hlatky, M. A. et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119, 2408-2416 (2009).
16. Pandit, K., Mukhopadhyay, P., Ghosh, S. & Chowdhury, S. Natriuretic peptides: diagnostic and therapeutic use. Indian J. Endocrinol. Metab. 15 (Suppl. 4), S345-S353 (2011).
17. Chen, H. & Burnett, J. C. Jr. Clinical application of the natriuretic peptides in heart failure. Eur. Heart J. 8 (Suppl. E), E18-E25 (2006). (Pubitemid 44408622)
18. Collins, S. P., Ronan-Bentle, S. & Storrow, A. B. Diagnostic and prognostic usefulness of natriuretic peptides in emergency department patients with dyspnea. Ann. Emerg. Med. 41, 532-545 (2003). (Pubitemid 36373522)
19. Clerico, A., Recchia, F. A., Passino, C. & Emdin, M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am. J. Physiol. Heart Circ. Physiol. 290, H17-H29 (2006).
20. Sagnella, G. A. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin. Sci. (Lond.) 95, 519-529 (1998).
21. Misono, K. S. et al. Structure, signaling mechanism and regulation of the natriuretic peptide receptor guanylate cyclase. FEBS J. 278, 1818-1829 (2011).
22. Maisel, A. S. et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347, 161-167 (2002). (Pubitemid 34764819)
23. Maisel, A. S. et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am. Heart J. 147, 1078-1084 (2004). (Pubitemid 38880968)
24. Maisel, A. S. et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly multinational study. J. Am. Coll. Cardiol. 41, 2010-2017 (2003). (Pubitemid 36677124)
25. Lukowicz, T. V. et al. BNP as a marker of diastolic dysfunction in the general population: importance of left ventricular hypertrophy. Eur. J. Heart Fail. 7, 525-531 (2005). (Pubitemid 40732982)
26. Richards, A. M. et al. Neuroendocrine prediction of left ventricular function and heart failure after myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart 81, 114-120 (1999). (Pubitemid 29119383)
27. Shah, K. B. et al. Natriuretic peptides and echocardiography in acute dyspnea: implication of elevated levels with normal systolic function. Eur. J. Heart Fail. 11, 659-667 (2009).
28. Lubien, E. et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 105, 595-601 (2002). (Pubitemid 34123434)
29. Bhalla, V., Scott, W. & Maisel, A. S. B-type natriuretic peptide: the level and the drug-partners in the diagnosis and management of congestive heart failure. Congest. Heart Fail. 10 (1 Suppl. 1), 3-27 (2004).
30. O'Connor, C. M. et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program. Am. Heart J. 159, 841-849 (2010).
31. Pimenta, J. et al. BNP at discharge in acute heart failure patients: is it all about volemia? A study using impedance cardiography to assess fluid and hemodynamic status. Int. J. Cardiol. 145, 209-214 (2010).
32. Valle, R. et al. Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels. Heart Fail. Rev. 16, 519-529 (2011).
33. Parrinello, G. et al. The usefulness of bioelectric impedance analysis in differentiating dyspnea due to decompensated heart failure. J. Cardiac Fail. 14, 676-686 (2008).
34. Maisel, A. S. et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J. Am. Coll. Cardiol. 44, 1328-1333 (2004).
35. DiSomma, S. et al. Use of BNP and bioimpedance to drive therapy in heart failure patients. Congest. Heart Fail. 16, 56-61 (2010).
36. Norman, K. et al. Bioimpedance vector analysis as a measure of muscle function. Clin. Nutr. 28, 78-82 (2009).
37. Piccoli, A., Pillon, L. & Dumler, F. Impedance vector distribution by sex, body mass index, and age in the United States: standard reference intervals as bivariate Z scores. Nutrition 18, 153-167 (2002). (Pubitemid 34158676)
38. McCullough, P. A., Omland, T. & Maisel, A. S. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev. Cardiovasc. Med. 4, 72-80 (2003). (Pubitemid 36701300)
39. Mueller, T., Gegenhuber, A., Poelz, W. & Haltmayer, M. Diagnostic accuracy of B-type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 91, 606-612 (2005). (Pubitemid 40559349)
40. Januzzi, J. L. et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur. Heart J. 27, 330-337 (2006). (Pubitemid 43100029)
41. Gegenhuber, A. et al. B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. Clinica Chimica Acta 370, 174-179 (2006). (Pubitemid 44137286)
42. Chen, A. A. et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) echocardiographic substudy. Eur. Heart J. 27, 839-845 (2006).
43. Moertl, D. et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J. Am. Coll. Cardiol. 53, 1783-1790 (2009).
44. Morgenthaler, N. G., Struck, J., Thomas, B. & Bergmann, A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin. Chem. 50, 234-236 (2004). (Pubitemid 38125732)
45. Maisel, A. S. et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J. Am. Coll. Cardiol. 55, 2062-2076 (2010).
46. Liangos, O. et al. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin. J. Am. Soc. Nephrol. 1, 43-51 (2006).
47. Damman, K. et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J. Card. Fail. 13, 599-608 (2007). (Pubitemid 47513536)
48. Smith, G. L. et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J. Am. Coll. Cardiol. 47, 1987-1996 (2006).
49. Chertow, G. M., Burdick, E., Honor, M., Bonventre, J. V. & Bates, D. W. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J. Am. Soc. Nephrol. 16, 3365-3370 (2005). (Pubitemid 46179340)
50. Soni, S., Ronco, C., Katz, N. & Cruz, D. N. Early diagnosis of acute kidney injury: the promise of novel biomarkers. Blood Purif. 28, 165-174 (2009).
51. Sarraf, M., Masoumi, A. & Schrier, R. W. Cardiorenal syndrome in acute decompensated heart failure. Clin. J. Am. Soc. Nephrol. 4, 2013-2026 (2009).
52. Ronco, C., Haapio, M., House, A. A., Anavekar, N. & Bellomo, R. Cardiorenal syndrome. J. Am. Coll. Cardiol. 52, 1527-1539 (2008).
53. Atlas, S. A. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J. Manag. Care Pharm. 13, 9-20 (2007).
54. Ronco, C. & Cruz, D. N. Biomarkers in cardio-renal syndromes. Ligand Assay 14, 340-349 (2009).
55. Mishra, J. et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 14, 2534-2543 (2003). (Pubitemid 37169339)
56. Mishra, J. et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. 15, 3073-3082 (2004). (Pubitemid 39578839)
57. Mori, K. & Nakao, K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int. 71, 967-970 (2007). (Pubitemid 46741985)
58. Nickolas, T. L., Barasch, J. & Devarajan, P. Biomarkers in acute and chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 17, 127-132 (2008). (Pubitemid 351253035)
59. Soni, S. S. et al. NGAL: a biomarker of acute kidney injury and other systematic conditions. Int. Urol. Nephrol. 42, 141-150 (2010).
60. Aghel, A., Shrestha, K., Mullens, W., Borowski, A. & Tang, W. H. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J. Cardiac Fail. 16, 49-54 (2010).
61. Maisel, A. S. et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL Evaluation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur. J. Heart Fail. 13, 846-851 (2011).
62. Hasse, M. et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J. Am. Coll. Cardiol. 57, 1752-1761 (2011).
63. Ichimura, T. et al. Kidney injury molecule 1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. Renal Physiol. 286, F552-F563 (2004). (Pubitemid 38233650)
64. Trof, R. J., Di Maggio, F., Leemreis, J. & Groeneveld, A. B. Biomarkers of acute renal injury and renal failure. Shock 26, 245-253 (2006).
65. Krawczeski, C. D. et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J. Am. Coll. Cardiol. 58, 2301-2309 (2011).
66. Przybylowski, P., Malyszko, J., Kozlowska, S. & Malyszko, J. S. Kidney injury molecule 1 correlates with kidney function in heart allograft recipients. Transplant. Proc. 43, 3061-3063 (2011).
67. Endre, Z. H. et al. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int. 79, 1119-1130 (2011).
68. Nickolas, T. L. et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J. Am. Coll. Cardiol. 59, 246-255 (2012).
69. Fonarow, G. C. et al. Factors identified as precipitated hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch. Intern. Med. 168, 847-854 (2008). (Pubitemid 351649267)
70. Meisner, M., Adina, H. & Scmidt, J. Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit. Care 10, R1 (2006).
71. Nijsten, M. et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit. Care Med. 28, 458-461 (2000). (Pubitemid 30120889)
72. Hausfater, P. et al. Serum procalcitonin measurement as diagnostic and prognostic marker in febrile adult patients presenting to the emergency department. Crit. Care 11, R60 (2006).
73. Delèvaux, I. et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann. Rheum. Dis. 62, 337-340 (2003). (Pubitemid 36363440)
74. Christ-Crain, M. et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am. J. Respir. Crit. Care Med. 174, 84-93 (2006). (Pubitemid 43955248)
75. Picariello, C., Lazzeri, C., Valente, S., Chiostri, M. & Gensini, G. F. Procalcitonin in acute cardiac patients. Intern. Emerg. Med. 6, 245-252 (2011).
76. Kafkas, N. et al. Procalcitonin in acute myocardial infarction. Acute Card. Care. 10, 30-36 (2008). (Pubitemid 351878178)
77. Linscheid, P. et al. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit. Care Med. 32, 1715-1721 (2004). (Pubitemid 39050523)
78. Delerme, S., Chenevier-Gobeaux, C., Doumenc, B. & Ray, P. Usefulness of B natriuretic peptides and procalcitonin in emergency medicine. Biomark. Insights 3, 203-217 (2008). (Pubitemid 351514036)
79. Hausfater, P. et al. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin. Infect. Dis. 34, 895-901 (2002). (Pubitemid 34229756)
80. Picariello, C. et al. Kinetics of procalcitonin in cardiogenic shock and in septic shock. Preliminary data. Acute Card. Care 12, 96-101 (2010).
81. Sinning, C. R. et al. Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circ. J. 75, 1184-1191 (2011).
82. Maisel, A. S. et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur. J. Heart Fail. 14, 278-286 (2012).
83. Doyle, I. R., Nicholas, T. E. & Bersten, A. D. Serum surfactant protein A levels in patients with cardiogenic pulmonary edema and adult respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 152, 307-317 (1995).
84. Doyle, I. R., Bersten, A. D. & Nicholas, T. E. Surfactant proteins A and B are elevated in plasma of patients with acute respiratory failure. Am. J. Respir. Crit. Care Med. 156, 1217-1229 (1997).
85. Bersten, A. D., Hunt, T., Nicholas, T. E. & Doyle, I. R. Elevated plasma surfactant protein B predicts development of acute respiratory distress syndrome in patients with acute respiratory failure. Am. J. Respir. Crit. Care Med. 164, 648-652 (2001). (Pubitemid 32801671)
86. Cheng, I. W. et al. Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit. Care Med. 31, 20-27 (2003). (Pubitemid 36151144)
87. De Pasquale, C. G. et al. Circulating surfactant protein B levels increase acutely in response to exercise-induced left ventricular dysfunction. Clin.Exp. Pharmacol. Physiol. 32, 622-627 (2005). (Pubitemid 41025823)
88. Bloomfield, S. M., McKinney, J., Smith, L. & Brisman, J. Reliability of S100B in predicting severity of central nervous system injury. Neurocrit. Care 6, 121-138 (2007). (Pubitemid 46934023)
89. Van Eldik, L. J. & Zimmer, B. D. Secretion of S-100 from rat C6 glioma cells. Brain Res. 436, 367-370 (1987). (Pubitemid 18003576)
90. Rainey, T., Lesko, M., Sacho, R., Lecky, F. & Childs, C. Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24h) time-point. Resuscitation 80, 341-345 (2009).
91. Wiesmann, M. et al. Outcome prediction in traumatic brain injury: comparison of neurological status, CT findings, and blood levels of S100B and GFAP. Acta Neurol. Scand. 121, 178-185 (2010).
92. Böhmer, A. E. et al. Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury. Neurosurgery 68, 1624-1630 (2011).
93. Ngyuen, D. N. et al. Elevated serum levels of S-100beta protein and neuron-specific enolase are associated with brain injury in patients with severe sepsis and septic shock. Crit. Care Med. 34, 1967-1974 (2006).
94. Snyder-Ramos, S. A. et al. Cerebral and extracerebral release of protein S100B in cardiac surgical patients. Anesthesia 59, 344-349 (2004). (Pubitemid 38489293)
95. Tsoporis, J. N. et al. S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction. Circ. Res. 106, 93-101 (2010).
96. Yan, S. F., Ramasamy, R. & Schmidt, A. M. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev. Mol. Med. 11, e9 (2009).
97. Li, J. P., Lu, L., Wang, L. J., Zhang, F. R. & Shen, W. F. Increased serum levels of S100B are related to the severity of cardiac dysfunction, renal insufficiency and major cardiac events in patients with chronic heart failure. Clin. Biochem. 44, 984-988 (2011).
98. Morgenthaler, N. G., Struck, J., Alonso, C. & Bergman, A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin. Chem. 52, 112-119 (2006). (Pubitemid 43032474)
99. Stoiser B. et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur. J. Clin. Invest. 36, 771-778 (2006). (Pubitemid 44569965)
100. Neuhold, S. et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure. J. Am. Coll. Cardiol. 52, 266-272 (2008). (Pubitemid 351957847)
101. Voors, A. et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from OPTIMAAL study. Eur. Heart J. 30, 1187-1194 (2009).
102. Kelly, D. et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodelling, and clinical heart failure in survivors of myocardial infarction. J. Cardiac Fail. 14, 739-745 (2008).
103. Peacock, W. F. et al. Short-term mortality risk in emergency department acute heart failure. Acad. Emerg. Med. 18, 947-958 (2011).
104. Jougasaki, M. et al. Adrenomedullin in experimental congestive heart failure: cardiorenal activation. Am. J. Physiol. 273 (4 Pt 2), R1392-R1399 (1997).
105. Hirayama, N. et al. Molecular forms of circulating adrenomedullin in patients with congestive heart failure. J. Endocrinol. 160, 297-303 (1999). (Pubitemid 29074701)
106. Daggubati, S. et al. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc. Res. 36, 246-255 (1997). (Pubitemid 27527349)
107. Jougasaki, M., Grantham, J. A., Redfield, M. M. & Burnett, J. C. Jr. Regulation of cardiac adrenomedullin in heart failure. Peptides 22, 1841-1850 (2001). (Pubitemid 34062802)
108. von Haehling, S. et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur. J. Heart Fail. 12, 484-491 (2010).
109. Klip, I. T. et al. Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart 97, 892-898 (2011).
110. Weinberg, E. O. et al. Expression and regulation of ST2, an interleukin 1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106, 2961-2966 (2002). (Pubitemid 35424749)
111. Shimpo, M. et al. Serum levels of the interleukin 1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109, 2186-2190 (2004). (Pubitemid 38625395)
112. Sanada, S. et al. IL 33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538-1549 (2007). (Pubitemid 46871338)
113. Mueller, T. et al. Increased plasma concentrations of soluble ST2 are predictive for 1 year mortality in patients with acute destabilized heart failure. Clin. Chem. 54, 752-756 (2008). (Pubitemid 351573718)
114. Shah, R. V., Chen-Tournoux, A. A., Picard, M. H., van Kimmenade, R. R. & Januzzi, J. L. Serum levels of the interleukin 1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ. Heart Fail. 2, 311-319 (2009).
115. Januzzi, J. L. Jr et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol. 50, 607-613 (2007). (Pubitemid 47199007)
116. Sharma, U. C. et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110, 3121-3128 (2004). (Pubitemid 39492008)
117. de Boer, R. A., Voors, A. A., Muntendam, P., van Gilst, W. H. & van Veldhuisen, D. J. Galectin-3: a novel mediator of heart failure development and progression. Eur. J. Heart Fail. 11, 811-817 (2009).
118. van Kimmenade, R. R. et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol. 48, 1217-1224 (2006).
119. Shah, R. V., Chen-Tournoux, A. A., Picard, M. H., van Kimmenade, R. R. & Januzzi, J. L. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur. J. Heart Fail. 12, 826-832 (2010).
120. Morrow, D. A. et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin. Chem. 53, 552-574 (2007). (Pubitemid 46580223)
121. Higgins, J. P. & Higgins, J. A. Elevation of cardiac troponin I indicates more than myocardial ischemia. Clin. Invest. Med. 26, 133-147 (2003). (Pubitemid 37011492)
122. Gerhardt, W., Nordin, G. & Ljungdahl, L. Can troponin T replace CK MBmass as "gold standard" for acute myocardial infarction ("AMI")? Scand. J. Clin. Lab. Invest. Suppl. 230, 83-89 (1999). (Pubitemid 29279360)
123. Weber, M. et al. Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome. Am. Heart J. 162, 81-88 (2011).
124. Dinh, W. et al. High sensitive troponin T and heart fatty acid binding protein: novel biomarker in heart failure with normal ejection fraction? A cross-sectional study. BMC Cardiovasc. Disord. 11, 41 (2011).
125. Panteghini, M. et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin.Chem. 50, 327-332 (2004). (Pubitemid 38156373)
126. Thygesen, K. et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur. Heart. J. 31, 2197-2204 (2010).
127. Reichlin, T. et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N. Engl. J. Med. 361, 858-867 (2009).
128. Peacock, F. W. 4th et al. Cardiac troponin and outcome in heart failure. N. Engl. J. Med. 358, 2117-2126 (2008).
129. Xue, Y., Clopton, P., Peacock, W. F. & Maisel, A. S. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur. J. Heart Fail. 1, 37-42 (2011).